AGI provides an advanced neurosurgical program specifically tailored to meet the needs of gene therapy, biologics, and implantable device developers targeting the central nervous system. Our capabilities encompass stereotactic neurosurgery, intrathecal, intraventricular, and intraparenchymal injections, deep-brain delivery, and spinal cord interventions, each supported by high-resolution MRI, CT, or ultrasound guidance. These models allow for the rigorous evaluation of biodistribution, expression kinetics, functional outcomes, and long-term safety in clinically relevant settings. We integrate electrophysiology, behavioral assays, neuroimaging, and multiplex biomarker profiling to provide sponsors with multidimensional datasets that capture both safety and efficacy. All procedures are performed under validated anesthetic and analgesic protocols, with perioperative monitoring ensuring animal welfare and reproducibility of outcomes.

 

Our neurosurgical platforms are adaptable to both exploratory and GLP-compliant programs, with regulatory documentation designed to support FDA and EMA submissions. By combining technical expertise, validated infrastructure, and decades of experience with translational neuroscience, Alpha Genesis delivers the precision, compliance, and reliability required to bridge the gap between exploratory CNS research and successful human clinical trials.